Networking to Optimize Dmd exon 53 Skipping in the Brain of mdx52 Mouse Model
The DOI matches its Crossref record.
Abstract
Duchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene that disrupt the open reading frame and thus prevent production of functional dystrophin proteins. Recent advances in DMD treatment, notably exon skipping and AAV gene therapy, have achieved some success aimed at alleviating the symptoms related to progressive muscle damage. However, they do not address the brain comorbidities associated with DMD, which remains a critical aspect of the disease. The mdx52 mouse model recapitulates one of the most frequent genetic pathogenic variants associated with brain involvement in DMD. Deletion of exon 52 impedes expression of two brain dystrophins, Dp427 and Dp140, expressed from distinct promoters. Interestingly, this mutation is eligible for exon skipping strategies aimed at excluding exon 51 or 53 from dystrophin mRNA. We previously showed that exon 51 skipping can restore partial expression of internally deleted yet functional Dp427 in the brain following intracerebroventricular (ICV) injection of antisense oligonucleotides (ASO). This was associated with a partial improvement of anxiety traits, unconditioned fear response, and Pavlovian fear learning and memory in the mdx52 mouse model. In the present study, we investigated in the same mouse model the skipping of exon 53 in order to restore expression of both Dp427 and Dp140. However, in contrast to exon 51, we found that exon 53 skipping was particularly difficult in mdx52 mice and a combination of multiple ASOs had to be used simultaneously to reach substantial levels of exon 53 skipping, regardless of their chemistry (tcDNA, PMO, or 2′MOE). Following ICV injection of a combination of ASO sequences, we measured up to 25% of exon 53 skipping in the hippocampus of treated mdx52 mice, but this did not elicit significant protein restoration. These findings indicate that skipping mouse dystrophin exon 53 is challenging. As such, it has not yet been possible to answer the pertinent question whether rescuing both Dp427 and Dp140 in the brain is imperative to more optimal treatment of neurological aspects of dystrophinopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is in sharp contrast to the human DMD gene, in which exon 53 seems easier to skip than exon 51 (Doisy et al., 2023).”
From Understanding Duchenne muscular dystrophy-associated brain pathology (2025) · cites this paper as Doisy et al., 2023
In the citing paper
“A combination of three AONs was required to improve exon 53 skipping to 25% (in the hippocampus), regardless of the chemistry used, highlighting the challenges of exon 53 skipping compared to exon 51 skipping in mdx52 mice.”
From Understanding Duchenne muscular dystrophy-associated brain pathology (2025) · cites this paper as Doisy et al., 2023
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 31
- Colombo, 2017, Assessing Mental Health in Boys with Duchenne Muscular Dystrophy: Emotional, Behavioural and Neurodevelopmental Profile in an Italian Clinical Sample, Eur. J. Paediatr. Neurol., 21, 639, 10.1016/j.ejpn.2017.02.007 · DOI · Paper page
- Hinton, 2009, Association of Autistic Spectrum Disorders with Dystrophinopathies, Pediatr. Neurol., 41, 339, 10.1016/j.pediatrneurol.2009.05.011 · DOI
- Maresh, 2023, Startle Responses in Duchenne Muscular Dystrophy: A Novel Biomarker of Brain Dystrophin Deficiency, Brain, 146, 252, 10.1093/brain/awac048 · DOI
- Ricotti, 2016, Neurodevelopmental, Emotional, and Behavioural Problems in Duchenne Muscular Dystrophy in Relation to Underlying Dystrophin Gene Mutations, Dev. Med. Child Neurol., 58, 77, 10.1111/dmcn.12922 · DOI · Paper page
- Mullard, 2023, FDA Approves First Gene Therapy for Duchenne Muscular Dystrophy, despite Internal Objections, Nat. Rev. Drug Discov., 22, 610, 10.1038/d41573-023-00103-y · DOI
- Beroud, 2007, Multiexon Skipping Leading to an Artificial DMD Protein Lacking Amino Acids from Exons 45 through 55 Could Rescue up to 63% of Patients with Duchenne Muscular Dystrophy, Hum. Mutat., 28, 196, 10.1002/humu.20428 · DOI · Paper page
- Bladen, 2015, The TREAT-NMD DMD Global Database: Analysis of More than 7000 Duchenne Muscular Dystrophy Mutations, Hum. Mutat., 36, 395, 10.1002/humu.22758 · DOI · Paper page
- Araki, 1997, Targeted Disruption of Exon 52 in the Mouse Dystrophin Gene Induced Muscle Degeneration Similar to That Observed in Duchenne Muscular Dystrophy, Biochem. Biophys. Res. Commun., 238, 492, 10.1006/bbrc.1997.7328 · DOI · Paper page
- Felisari, 2000, Loss of Dp140 Dystrophin Isoform and Intellectual Impairment in Duchenne Dystrophy, Neurology, 55, 559, 10.1212/WNL.55.4.559 · DOI
- Hendriksen, 2020, ENMC 249th workshop study group 249th ENMC International Workshop: The Role of Brain Dystrophin in Muscular Dystrophy: Implications for Clinical Care and Translational Research, Hoofddorp, The Netherlands, November 29th-December 1st 2019, Neuromuscul. Disord., 30, 782, 10.1016/j.nmd.2020.08.357 · doi:10.1016/j.nmd.2020.08.357
- 2023, Global Prevalence of Intellectual Developmental Disorder in Dystrophinopathies: A Systematic Review and Meta-Analysis, Dev. Med. Child. Neurol., 65, 734, 10.1111/dmcn.15481 · DOI
- Taylor, P.J., Betts, G.A., Maroulis, S., Gilissen, C., Pedersen, R.L., Mowat, D.R., Johnston, H.M., and Buckley, M.F. (2010). Dystrophin Gene Mutation Location and the Risk of Cognitive Impairment in Duchenne Muscular Dystrophy. PLoS ONE, 5. · DOI · Paper page
- Saoudi, 2023, Partial Restoration of Brain Dystrophin by Tricyclo-DNA Antisense Oligonucleotides Alleviates Emotional Deficits in Mdx52 Mice, Mol. Ther. Nucleic Acids, 32, 173, 10.1016/j.omtn.2023.03.009 · DOI
- Saoudi, A., Fergus, C., Gileadi, T., Montanaro, F., Morgan, J.E., Kelly, V.P., Tensorer, T., Garcia, L., Vaillend, C., and Muntoni, F. (2023). Investigating the Impact of Delivery Routes for Exon Skipping Therapies in the CNS of DMD Mouse Models. Cells, 12. · DOI
- Aoki, 2012, Bodywide Skipping of Exons 45-55 in Dystrophic Mdx52 Mice by Systemic Antisense Delivery, Proc. Natl. Acad. Sci. USA, 109, 13763, 10.1073/pnas.1204638109 · DOI · Paper page
- Blau, 1983, Cytoplasmic Activation of Human Nuclear Genes in Stable Heterocaryons, Cell, 32, 1171, 10.1016/0092-8674(83)90300-8 · DOI · Paper page
- Relizani, 2022, Palmitic Acid Conjugation Enhances Potency of Tricyclo-DNA Splice Switching Oligonucleotides, Nucleic Acids Res., 50, 17, 10.1093/nar/gkab1199 · DOI
- Paxinos, G., and Franklin, K.B.J. (2001). The Mouse Brain in Stereotaxic Coordinates, Academic Press. [2nd ed.].
- Aupy, 2020, Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in Mdx52 Mice, Mol. Ther. Methods Clin. Dev., 17, 1037, 10.1016/j.omtm.2020.04.025 · DOI · Paper page
- Mitrpant, 2009, Rational Design of Antisense Oligomers to Induce Dystrophin Exon Skipping, Mol. Ther., 17, 1418, 10.1038/mt.2009.49 · DOI
- Saoudi, 2021, Emotional Behavior and Brain Anatomy of the Mdx52 Mouse Model of Duchenne Muscular Dystrophy, Dis. Model. Mech., 14, dmm049028, 10.1242/dmm.049028 · DOI · Paper page
- Kaman, 2006, Exploring the Frontiers of Therapeutic Exon Skipping for Duchenne Muscular Dystrophy by Double Targeting within One or Multiple Exons, Mol. Ther., 14, 401, 10.1016/j.ymthe.2006.02.022 · DOI
- Kim, 2022, Exon-Skipping Antisense Oligonucleotides for Cystic Fibrosis Therapy, Proc. Natl. Acad. Sci. USA, 119, e2114858118, 10.1073/pnas.2114858118 · DOI
- Echigoya, 2015, Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45-55 with a Cocktail of Vivo-Morpholinos in Mdx52 Mice, Mol. Ther. Nucleic Acids, 4, e225, 10.1038/mtna.2014.76 · DOI
- Echigoya, 2019, Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene, Mol. Ther., 27, 2005, 10.1016/j.ymthe.2019.07.012 · DOI
- Spitali, 2013, DMD Transcript Imbalance Determines Dystrophin Levels, FASEB J., 27, 4909, 10.1096/fj.13-232025 · DOI · Paper page
- Hiller, 2020, Premature Termination Codons in the DMD Gene Cause Reduced Local mRNA Synthesis, Proc. Natl. Acad. Sci. USA, 117, 16456, 10.1073/pnas.1910456117 · DOI
- Clemens, 2020, Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial, JAMA Neurol., 77, 982, 10.1001/jamaneurol.2020.1264 · DOI · Paper page
- Kudoh, 2005, A New Model Mouse for Duchenne Muscular Dystrophy Produced by 2.4 Mb Deletion of Dystrophin Gene Using Cre-loxP Recombination System, Biochem. Biophys. Res. Commun., 328, 507, 10.1016/j.bbrc.2004.12.191 · DOI · Paper page
- Doorenweerd, 2017, Timing and Localization of Human Dystrophin Isoform Expression Provide Insights into the Cognitive Phenotype of Duchenne Muscular Dystrophy, Sci. Rep., 7, 12575, 10.1038/s41598-017-12981-5 · DOI · Paper page
- Hashimoto, Y., Kuniishi, H., Sakai, K., Fukushima, Y., Du, X., Yamashiro, K., Hori, K., Imamura, M., Hoshino, M., and Yamada, M. (2022). Brain Dp140 Alters Glutamatergic Transmission and Social Behaviour in the Mdx52 Mouse Model of Duchenne Muscular Dystrophy. Prog. Neurobiol., 216. · DOI · Paper page
Cited by
Understanding Duchenne muscular dystrophy-associated brain pathology
Verhaeg, M. A. T., Govaarts, R., & van Putten, M. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052302 · Cited by 5
Self-citation
Metadata
- Authors
- Doisy, M., Vacca, O., Fergus, C., Gileadi, T., Verhaeg, M., Saoudi, A., Tensorer, T., Garcia, L., Kelly, V. P., Montanaro, F., Morgan, J. E., van Putten, M., Aartsma-Rus, A., Vaillend, C., Muntoni, F., & Goyenvalle, A.
- Affiliations
- Université Paris-Saclay, UVSQ, Inserm, END-ICAP, 78000 Versailles, France
- School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, D02 R590 Dublin, Ireland
- Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, 30 Guildford Street, London WC1N 1EH, UK
- Department of Human Genetics, Leiden University Medical Center, 2333ZA Leiden, The Netherlands
- SQY Therapeutics-Synthena, UVSQ, 78180 Montigny le Bretonneux, France
- Université Paris-Saclay, CNRS, Institut des Neurosciences Paris-Saclay, 91400 Saclay, France
- ORCID
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2023-12-07
- Volume
- 11
- Issue
- 12
- Pages
- 3243
- ISSN
- 2227-9059
- Cited by
- 13
- References
- 0
- Language
- en
- Funders
- European Union (847826)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Networking to Optimize Dmd exon 53 Skipping in the Brain of mdx52 Mouse Model. https://app.cochat.ai/papers/10.3390/biomedicines11123243
- The paper
- Doisy, M., Vacca, O., Fergus, C., Gileadi, T., Verhaeg, M., Saoudi, A., Tensorer, T., Garcia, L., Kelly, V. P., Montanaro, F., Morgan, J. E., van Putten, M., Aartsma-Rus, A., Vaillend, C., Muntoni, F., & Goyenvalle, A. (2023). Networking to Optimize Dmd exon 53 Skipping in the Brain of mdx52 Mouse Model. Biomedicines. https://doi.org/10.3390/biomedicines11123243
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.